Drug intelligence / Profile preview

CI-1012

Development stage: Phase 1
Lead developer: Pfizer
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

CI-1012 is a novel benzamide-disulfide small molecule developed as an antiviral agent targeting HIV-1 and HIV-2. Its mechanism of action involves inhibition of the HIV nucleocapsid protein NCp7 by disrupting zinc finger motifs, thereby interfering with viral replication. The compound was originally developed by Pfizer in collaboration with the National Institutes of Health (USA). It reached Phase 2 clinical trials for the treatment of HIV infections but development was discontinued[1][3][7].

Other names: PD 159206PD159206PD-159206

Targets

NCp7 (Human immunodeficiency virus type 1 nucleocapsid protein)

Beyond the preview

Go deeper on CI-1012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CI-1012.

Explore the full profile